Trial reportBMC ophthalmology2025
Efficacy of combined topical nepafenac 0.3% with suprachoroidal injection of triamcinolone acetonide using a modified custom needle in pseudopkakic cystoid macular edema.
Trial report in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04690608 (Resistant Diabetic Macular Edema and Suprachoroidal Injection), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Resistant Diabetic Macular Edema and Suprachoroidal Injection
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe present study evaluated the efficacy of combined use of suprachoroidal injection of triamcinolone acetonide (SCTA) using a modified custom needle with topical nepafenac 0.3% in the treatment of pseudophakic cystoid macular edema (PCME).
methodsA prospective randomized study that included sixty eyes of 60 patients with PCME. Patients were divided in two groups, group (1) included 30 patients who received topical nepafenac 0.3% eye drops alone and group (2) that included 30 patients who received a single SCTA (4 mg/0.1 ml) combined with topical nepafenac 0.3% eye drops.
resultsIn group 1, the central macular thickness (CMT) decreased from 457.4 ± 81.4 um to 252.9 ± 54.6 um after 12 months. In respect to group 2, CMT declined from 455.1 ± 79.6 um to 213.7 ± 14.2 um after 12 months. The CMT was more significantly reduced in group 2 after 1,3,6,9 and 12 months (p value < 0.001). Group 1 showed improvement of best corrected visual acuity (BCVA) by log MAR from 0.9(0.8-1) to 0.2(0.1-0.4) after 12 months, while group 2 showed improvement from 0.9(0.8-1) to 0.1(0-0.1) after 12 months. More significant improvement of BCVA was detected in group 2 after 1,3,6 and 9 months with p value < 0.001 and after 12 months with p value 0.001.
conclusionCombined SCTA using this modified custom needle with topical nepafenac 0.3% resulted in better anatomical and functional results in PCME patients compared to topical nepafenac 0.3% alone. The study was prospectively registered with clinical trial.gov ID (NCT04690608) in 27-12-2020.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.